Overview

Clavulanic Acid for the Treatment of Cocaine Use Disorder

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
A dose escalation study to assess the efficacy and safety of Clavulanic Acid (CLAV) vs. placebo (PBO) for the treatment of cocaine use disorder (CUD)
Phase:
Phase 2
Details
Lead Sponsor:
Temple University
Collaborators:
Medical University of South Carolina
Research Foundation for Mental Hygiene, Inc.
University of Pennsylvania Perelman School of Medicine
Treatments:
Clavulanic Acid
Clavulanic Acids